The interplay between anticancer challenges and the microbial communities from the gut.

Hobson, Claire Amaris; Bonacorsi, Stéphane; Baruchel, André; Tenaillon, Olivier; Birgy, André

Hobson, Claire Amaris; Bonacorsi, Stéphane; Baruchel, André; Tenaillon, Olivier; Birgy, André.

Affiliation

Hobson CA; IAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
Bonacorsi S; IAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
Baruchel A; Laboratoire de Microbiologie, Hôpital Robert Debré, AP-HP, 75019, Paris, France.
Tenaillon O; Service d'Immuno-Hématologie Pédiatrique, Hôpital Robert Debré, AP-HP, 75019, Paris, France.
Birgy A; IAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.

Eur J Clin Microbiol Infect Dis ; 41(5): 691-711, 2022 May.

Article in En | MEDLINE | ID: mdl-35353280

Subject(s)

Anti-Infective Agents; Gastrointestinal Microbiome; Microbiota; Neoplasms; Bacteria; Dysbiosis/microbiology; Gastrointestinal Microbiome/physiology; Humans; Neoplasms/therapy

Key words

Anticancer drugs; Gut microbiota; Microbiology; Mutagenesis; Oncology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Microbiota / Gastrointestinal Microbiome / Anti-Infective Agents / Neoplasms Limits: Humans Language: En Journal: Eur J Clin Microbiol Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Year: 2022 Type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google